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A (mtTFA) and indirect role via up-regulation of the p53R2
expression2-4. Recently more than 6 kinds of P53 isoform have
been reported and they played the different role in DNA repair
pathways, cell-cycle checkpoints and cell apoptosis5. P53 and its
different p53 isoforms play what kind of role in mitochondrial
toxicity induced by NRTIs is unclear. In this study, we identiﬁed
the role of wild type p53 and its isoforms (N40P53 and N133P53)
in mitochondrial toxicity induced by AZT and oxidative stress.
In this study we treated the A549 p53+/+, H1299 N40 P53+/+,
H1299 N133P53+/+ and H1299 P53-/- cell lines with 5 to 200
μM AZT for 12 hours for studying cell death and the expression
of p53R2, p21 and bax via p53R2 (Bax, P21) pGL3-Luciferase
reporter gene assay, real-time PCR and Western Blotting; treated
cells with 30uμM AZT for 5 weeks, 10 weeks and 1μM H2O2
for 1 hour/week to study the mtDNA mutation, mtDNA deletion
and mitochondrial toxicity. The cells were treated with p53R2
interference RNA to study the p53R2 how regulated the DNA Pol
γ capability.
The result showed that A549 p53+/+ cell death is more sensi-
tive to high concentration of AZT. The increased cell death was
detected from 120 uM of AZT and more that 80% cell were into
apaotosis in 2000 μM AZT. But other three cell lines have strong
tolerance to AZT toxicity. They are only less than 10% cell death
in 2000 μM AZT. The results from report gene assay and real-time
PCR assay suggested that wild type p53, N40 P53, N133P53 played
different role in p53R2, P21 and Bax promoters. All of wild type
and isoform P53 up-regulated the p53R2 expression, but isoform
P53 played a domain negative regulation in Bax expression. The
p21 expression was co-stimulated by wilde-type P53 and N40,
N133P53. D-loop of mtDNA mutation and mtDNA quatitiy assay
showed that A549 p53+/+ cell has lower mtDNA mutation rate
and almost no mtDNA loss following 5 weeks AZT stress. N40
P53,N133P53 cells have lower mtDNA mutation too, but mtDNA
loss is signiﬁcant higher than that in A549 P53 +/+ cells. H1299
P53 null cells has higher mtDNA mutation rate and mtDNA loss
than that in wild-type P53 and N40 P53, N133P53 isoform cells.
Conclusion: Both wild type and N40 P53,N133P53 isoform p53
play protect role in AZT induced mitochondrial toxicity. The
P53R2 would be involved in the centrol molecular pathway of p53
reduced mtDNA mutation and mtDNA loss induced by AZT
PP-146 Incidence and characterization of acute HIV-1
infection among high-risk self-identiﬁed men who
have sex with men in Beijing, China
Xiaojie Huang*, Haiying Li, Zhiying Liu, Caiping Guo,
Yanqing Gao, Zaicun Li, Yan Fu, Tong Zhang, Dexi Chen,
Xiaoning Xu, Hao Wu. Beijing YouAn Hospital, Capital Medical
University
Objective: To investigate the HIV incidence and the baseline
demographic data, clinical characteristics of acute HIV infec-
tions among self-identiﬁed men who have sex with men (MSM)
population in Beijing.
Methods: From May 2007 to February 2009, a hospital-based
cohort of HIV-uninfected MSM was established for a natural his-
tory study of HIV-1 infection. The cohort was followed every
two months to determine HIV incidence by pooling nucleic acid
testing (NAT) of third-generation enzyme immunoassay (EIA)-
negative samples.
Results: After screening 2861 individuals, a hospital-based co-
hort of 1529 uninfected high-risk MSM was established. During
1147.575 person-years of follow-up, 8424 samples were screened
for acute HIV infection by pooling nucleic acid testing (NAT)
of third-generation enzyme immunoassay (EIA)-negative sam-
ples (n =8221). HIV-prevalence at screening was 9.29% posing a
challenge in HIV-negative MSM. 63 infections occurred yielding
seroincidence rate of 5.49 per 100 person-years. 15 acute HIV-
infected subjects were identiﬁed by pooled NAT. Median HIV RNA
was 5.34 copies per milliliter (log10 viral load (VL) =220,000).
Conclusions: HIV prevalence in MSM population is signiﬁcantly
greater than that in the general population, which reﬂects the
current epidemic in Beijing and justiﬁes prevention programs
aimed at this group. This high-risk population may be suitable for
future studies on acute HIV infection, HIV treatment, vaccine,
and prevention of onward transmission strategies.
PP-147 Liver injury in HIV-1-infected patients receiving
non-nucleosides reverse transcriptase
inhibitors-based antiretroviral therapy
Zaicun Li *, Lili Dai, Yanqing Gao, Haiying Li, Xiaojie Huang,
Caiping Guo, Tong Zhang, Hao Wu. Clinical center for STDs and
AIDS at Beiijng Youan Hospital, Capital Medical University
Objectives: To study the features of liver injury in HIV-1-
infected patients receiving non-nucleosides reverse transcriptase
inhibitors-based antiretroviral therapy (ART).
Methods: 75 patients receiving non-nucleosides reverse tran-
scriptase inhibitors-based ART were retrospectively studied. The
patients were divided into 2 groups: liver injury group (n=45) and
non-liver injury group (n=30). The features of liver injury were
analysed. The prevelance of HBV and/or HCV, hepatotoxic drugs
use and NVP or EFV use were compared between two groups.
Results: 45 (60%) patients, 31 (68.9%) males and 14 (31.1%)
females, aged 12–52 years, averaged 39±9 years, experienced
at least one episode of liver injury. 40 (53.3%) co-infected with
HBV and/or HCV, 42 (56%) patients had concomitant use of an-
tituberculosis drugs, 46 (61.3%) and 29 (38.7%) received regimen
containing NVP or EFV, respectively. Grade 1 liver injury were
observed in 26 (34.7%) patients, grade 2 in 16 (21.3%), grade 3 in
2 (2.7%) and grade 4 in 1 (1.3%), respectikvely. 3 (4%) patients dis-
continued ART due to liver injury. There were 29 (64.4%) patients
coinfected with HBV and/or HCV, 32 (71.1%) received regimens
containing NVP, and 30 (66.7%) had concomitant use of antibu-
berculosis drugs in liver injury group, respectively, signiﬁcantly
higher than those in non-liver injury group [11 (36.7%), 14 (46.7%)
and 12 (40%), respectively. P=0.018, 0.033, 0.023, respectively].
Conclusions: Liver injury in HIV-1-infected patients receiving
non-nucleosides reverse transcriptase inhibitors-based antiretro-
viral therapy was mild to moderate, those who coinfeted with
HBV and/or HCV, had cocomitant use of antibuberculosis drugs
or cotrimoxazole and received a regimen containing NVP were
prone to liver injury.
PP-148 Simultaneous disseminated mycobacterium avium
complex (MAC) and pulmonary cryptococcosis in
an AIDS patient: presentation of immune
reconstitution inﬂammatory syndrome (IRIS)
requiring corticosteroid therapy
Azadeh Nasseh*, Baya Omidnia, Ladan Ahmadi. Department of
Medicine; Lenox Hill Hopsital; New York, NY, USA
Introduction: Immune reconstitution syndrome, caused by
restoration of the capacity to mount an inﬂammatory response,
can lead to morbidity and mortality in HIV patients.
Case description: A 38 y/o presented with fever and weight loss.
HIV test was positive and blood culture grew Crytococcus Neofor-
mans. CD4 was 45 cells/ml and viral load (VL) 800,000 copies/ml.
Chest CT revealed hilar lymphadenopathy and RLL lesion. Few
weeks into treatment with Amphotericin B and subsequently Flu-
conazole, combination antiretroviral therapy (CART) was added
to PCP and MAC prophylaxis. After 4 weeks, he presented with
fever and cervical lymphadenopathy. CD4 was 322, VL 80,000.
Bronchial washing showed Cryptococcus and MAC. Amphotericin
B, Rifabutin, Ethambutol and Azithromycin were started. One
month later fever and lymphadenopathy continued. Biopsy of
a node showed necrotizing granuloma due to MAC. IRIS with
Disseminated MAC was diagnosed and considering progressive
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nature of the symptoms, CART was discontinued; which led to
improvement of the symptoms. Reintroducing CART after 8 weeks
resulted in recurrence of the same symptoms, at which point
prednisone was added to the ongoing MAC and CART treatment.
After 4 weeks CD4 is 107, VL 957, and patient has tolerated CART
with no complications and Prednisone is being tapered.
Discussion: Currently there are no accepted criteria for diagnosis
of IRIS. The need to stop CART in cases of severe IRIS is controver-
sial. In some cases like ours, where temporary discontinuation of
CART may not be effective or appropriate, adding corticosteroids
to the regimen can help control the exaggerated inﬂammatory
response.
PP-149 Patient centered peer based program to improve
adherence to HIV therapy. The HATS-PC initiative
Adetunji Adejumo, Cynthia Lee*, Wafaar El-Sadr,
Sharon Mannheimer. Div. of Infectious Disease, Dept. of
Medicine, Harlem Hosp Ctr., Columbia University, New York, USA
Background: The success of HIV treatment depends on high
adherence rate (>95%) to antiretroviral therapy (ART). With
over one-third of patients reporting active substance use, we
estimated that over half may be non adherent or at risk of non
adherence.
Methods: HATS-PC program is a patient-centered, multidisci-
plinary adherence support team that includes peer worker, case
worker, HIV primary care providers and a program coordina-
tor/health educator. Peer workers are HIV-infected individuals
from the same community, adherent to ART, with good commu-
nication skills and commitment to helping others. Program peer
workers received a 6-week training focused on HIV/ART, and
counseling techniques. Adherence is measured by a 7-day self
report assessment, evaluation of laboratory data at baseline,
then quarterly and stage of behavioral change.
Results: 21 HIV-infected patients were enrolled in 2008, assigned
to 2 peer workers. 66% (n =14) female and 33% (n = 7) male, mean
age 43.2y (range 28-59). At program entry, majority 81% (n = 17)
had HIV RNA between 480 copies/ml and ≥100,000 copies/ml
(71% women, mean age 37, mean CD4 258 cells/uL).
The main reason for non-adherence was substance use (43%).
Other reasons were depression (23%), communication barrier
(14%) and medication side effect (9%).
62% (n = 13) graduated from the program having achieved a
target of >95% adherence for 6 months.
LESSONS LEARNED: Peer based adherence support can improve
adherence to treatment. Additionally, there is need for speciﬁc
interventions to address substance use in this population.
PP-150 To investigate the change of peripheral dendritic
cell (DC) subsets in individuals infected with HIV
who were treated with Ailing granule, a
traditional Chinese drug
Jianan Wei*,1, Jing Liu1, Fusheng Wang2, Chunxin Song1,
Zheng Zhang2, Yan Jin1, Liuhua Xue1, Wei Zhou1, Xuan Xu1,
Xiazhen Huang1. 1Guang’an Men Hospital Afﬁliated to China
Academy of Chinese Medical Sciences; 2302 Military Hospital of
China
Objective: To investigate the change of peripheral dendritic cell
(DC)subsets in individuals infected with HIV who were treated
with Ailing granule, a traditional Chinese drug.
Method: 17 cases who had not taken anti-viral medicines were
treated with AiLing granule for 9 months.11 cases were set as
normal control. The percentages of PDC and MDC were deter-
mined by ﬂow cytometry. At the same time, the ability of PDC to
produce IFN-α was also determined.
Results: The percentage of MDC in individuals treated with Ailing
granule for 3 or 9 months was signiﬁcantly higher than that before
the treatment, and returned to a normal level. The percentage
of PDC in individuals treated for 9 months was signiﬁcantly higher
than that before-treatment and also returned to a normal level.
The value of IFN-α in individuals treated for 9 months was el-
evated and had statistically signiﬁcant difference as compared
with that before treatment.
Conclusion: Ailing granule could increase to a certain extent the
percentage of MDC and PDC and elevate the ability of PDC to
produce IFN-α, thus raising immunity of the infected individuals.
PP-151 New treatment of cutaneous herpes zoster and
control of neurolgia by plumeria alba extract
James Muthotho*. Health Promotion - King Baudouin Foundation
Kenya
Introduction: The herpes zoster infection is on the increase.
The antiviral drugs and analgesics infection are very expensive,
secondary bacteria infection is a problem,herpes acute pain and
post-herpetic neuralgia are a major cause of HIV/AIDS patient
morbidity. Health workers in Kenya have come with an ointment
made from plumeria alba plant, Chlorhexidine gluconate and
cetrimide for treating herpes zoster. This to eliminate acute neu-
ralgia, post herpetic neuralgia, kill the virus, prevent secondary
bacterial infection and control itching. To reduce these problems
herb extracts were tested for their efﬁcacy.
Method: Phytochemistry was done & HEP2 cells was usedto grow
virus. Extract was made in ﬁne powder form,diluted in petroleum
jelly 6mg plumeria alba extract in 100 g, chlorhexdine gluconate
0.001125 mg and cetrimide 0.01125 mg is added to prevent
secondary bacteria infection. Nontoxic extracts were applied on
herpes blisters. Neutralization of pain and inhibition of viruses
were monitored.
Results: Extract has polyphenolic compounds, and non-toxic car-
diac glycosides. This extract inhibits the growth of viruses when is
diluted up to 1:32. When it was applied on the patient’s blisters 3
times daily, the culture from vesical ﬂuid were negative within 3
days. The neurogia pain was eliminated within 10 minutes. while
those who were treated with antiviral drugs continued to have
post herpetic neuralgia. This ointment preparation, plumeria
alba has polyphenolics which kills the viruses and also eliminates
neuralgia during active infection and post herpetic neuralgia and
bacteria infection.
Observation: The patients treared with this drug d’nt get recur-
rent Herpes and post herpartic neuralgia
PP-152 Prevalence of hepatitis B, hepatitis C and human
immunodeﬁciency virus among young blood
donors in Tripura, India
Deepak Singh Bais *,1, Paramita Das2, Pankaj Deo1. 1Huazhong
University of Science and Technology, Tongji Hospital,
Department of Clinical Medicine, Wuhan, China; 2Tripura
University, Agartala Government Medical College, Blood Bank
Department, G.B. Pant Hospital, Tripura, India
Objective: Hepatitis C virus (HCV), hepatitis B virus (HBV) and
human immunodeﬁciency virus (HIV) are three most important
viral agents, responsible for transfusion transmitted infections
(TTIs). Study aim was to estimate the prevalence of HBV, HCV
and HIV among young blood donors in south Asian country, India.
Methods: Seroprevalence of HBsAg, anti-HCV and anti-HIV1/2
was studied among 13,671 young blood donors (mean age 18±9
yrs) from February 2007 to August 2008 at Blood Bank Depart-
ment, G.B. Pant Hospital, Tripura, India. Samples were screened
by using third generation ELISA Among total, 17.2% (n=2351)
were volunteers and rest were replacement donors. Standard-
ized questionnaire was designed to access social and clinical risk
factors, informed consent was taken from each participant.
Results: Among 13671, total seropositive rate was 2.71% (n=370),
